ArticleEvidence-based complementary and alternative medicine : eCAM2020
Orlistat-Induced Gut Microbiota Modification in Obese Mice.
Article in Evidence-based complementary and alternative medicine : eCAM, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- A diethylene glycol oligomer squalene derivative modulates metabolic gene expression in ob/ob mice.EXCLI journal · 2026Article
- Immunometabolic alterations induced by GBD surgery and adjunct pharmacotherapy with metformin, orlistat, statins, and ACE inhibitors.Molecular biology reports · 2025Article
- Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review.Journal of advanced research · 2025Review
- Orlistat ameliorates lipid dysmetabolism in high-fat diet-induced mice via gut microbiota modulation.Frontiers in microbiology · 2025Article
- Harnessing Prebiotics to Improve Type 2 Diabetes Outcomes.Nutrients · 2024Review
- A two-sample bidirectional Mendelian randomization analysis investigates associations between gut microbiota and type 2 diabetes mellitus.Frontiers in endocrinology · 2024Article
- Gut microbiota and therapy for obesity and type 2 diabetes.Frontiers in endocrinology · 2024Review
- Evaluation of gut microbiota alterations following orlistat administration in obese mice.Frontiers in endocrinology · 2024Article
- Perilla, sunflower, and tea seed oils as potential dietary supplements with anti-obesity effects by modulating the gut microbiota composition in mice fed a high-fat diet.European journal of nutrition · 2023Article
- Integrated fecal microbiota and metabolomics analysis of the orlistat intervention effect on polycystic ovary syndrome rats induced by letrozole combined with a high-fat diet.Journal of ovarian research · 2023Article
- Exploring the causal effects of the gut microbiome on serum lipid levels: A two-sample Mendelian randomization analysis.Frontiers in microbiology · 2023Article
- The lipid-lowering effects of fenugreek gum, hawthorn pectin, and burdock inulin.Frontiers in nutrition · 2023Article
- Roles of Gut Microbiome in Bone Homeostasis and Its Relationship with Bone-Related Diseases.Biology · 2022Review
- Grape seed and skin extract, a potential prebiotic with anti-obesity effect through gut microbiota modulation.Gut pathogens · 2022Article
- Adipose triglyceride lipase mediates lipolysis and lipid mobilization in response to iron-mediated negative energy balance.iScience · 2022Article
- Impact of the herbal medicine,Frontiers in pharmacology · 2022Article
- Structural characteristics of polysaccharide fromFrontiers in nutrition · 2022Article
- Anti-obesity effect ofFrontiers in nutrition · 2022Article
- Lorcaserin and phentermine exert anti-obesity effects with modulation of the gut microbiota.Frontiers in microbiology · 2022Article
- Orlistat and ezetimibe could differently alleviate the high-fat diet-induced obesity phenotype by modulating the gut microbiota.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAccumulating evidence has indicated that alterations of gut microbiota have been involved in various metabolic diseases. Orlistat, a reversible inhibitor of pancreatic and gastric lipase, has beneficial effects on weight loss and metabolism. However, the effect of orlistat on the composition of gut microbiota remains unclear.
objectiveWe aimed to explore the effect of orlistat on gut microbiota in high-fat diet (HFD) fed C57BL/6J obese mice.
methodsC57BL/6J mice were randomly divided into three groups: control (NCD), HFD, and HFD + orlistat (ORL). Mice in the NCD group were fed chow diet, while the other groups were fed HFD for 6 months, and orlistat was added in the final 3 months in the HFD + ORL group. After sacrifice, body weight and metabolic parameters were assessed, and the gut microbial composition was analyzed by 16S rRNA gene sequencing.
resultsOrlistat treatment exerted beneficial effects on body weight, plasma cholesterol, and glucose tolerance. Meanwhile, orlistat treatment modified the gut microbiota, presenting as reduced total microbial abundance and obvious upregulated bacteria. Moreover, the upregulated bacteria correlated with several metabolic pathways.
conclusionsOrlistat may exert beneficial effects on body weight and glucose tolerance through modifying the composition of gut microbiota.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.